NewEdge Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

NewEdge Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,350	Closed	-$616K	–	3951
2024 Q3	$616K	Buy	+21,350	New	+$611K	﹤0.01%	1353
2023 Q4	–	Sell	-7,274	Closed	-$186K	–	3792
2023 Q3	$186K	Buy	7,274 +532	+8%	+$14.1K	﹤0.01%	1654
2023 Q2	$177K	Sell	6,742 -907	-12%	-$24K	﹤0.01%	1678
2023 Q1	$200K	Buy	7,649 +1,384	+22%	+$37.1K	﹤0.01%	1545
2022 Q4	$172	Buy	+6,265	New	+$167K	﹤0.01%	3316

Other funds holding FTXH

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewEdge Advisors's FTXH Position: Q4 2024 in Review

NewEdge Advisors sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q4 2024, closing a stake of 21,350 shares — an estimated $616K sold.

NewEdge Advisors first reported a position in FTXH in Q4 2022 and held it in 5 quarters. The position peaked at $616K in Q3 2024. 21 funds tracked by Wall St. Rank hold FTXH as of Q4 2024.

NewEdge Advisors reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q4 2024 after selling out during the quarter.
NewEdge Advisors sold 21,350 First Trust Nasdaq Pharmaceuticals ETF shares in Q4 2024, an estimated $616K.
NewEdge Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and held it in 5 quarters.
NewEdge Advisors's First Trust Nasdaq Pharmaceuticals ETF position peaked at $616K in Q3 2024.
21 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q4 2024.

Based on NewEdge Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.